Claritin Generic Competition Grows As Impax Version Granted FDA Approval
This article was originally published in The Tan Sheet
Executive Summary
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product
You may also be interested in...
Schering Compliance Appointment Reflects Hassan’s Pursuit Of GMP Closure
Schering-Plough's appointment of Brent Saunders as senior VP-global compliance & business practices is indicative of CEO Fred Hassan's aggressive strategy of addressing the firm's compliance issues
Schering Compliance Appointment Reflects Hassan’s Pursuit Of GMP Closure
Schering-Plough's appointment of Brent Saunders as senior VP-global compliance & business practices is indicative of CEO Fred Hassan's aggressive strategy of addressing the firm's compliance issues
Schering Compliance Appointment Reflects Hassan’s Pursuit Of GMP Closure
Schering-Plough's appointment of Brent Saunders as senior VP-global compliance & business practices is indicative of CEO Fred Hassan's aggressive strategy of addressing the firm's compliance issues